Abstract 280P
Background
Abiraterone (ABI) and enzalutamide (ENZ) are preferred as 1st-line therapy for mCRPC. Ra-223 has survival impacts for mCRPC with symptomatic bone mets but no benefit in combination with ABI/ENZ. Very few pts wanted to receive chemotherapy due to old age and could not afford NGS or PSMA scan. 40% pts received Ra-223 as 2nd-line therapy after ABI/ENZ and lymph nodes (LNs) < 3 cm in short-axis were enrolled in the ALSYMPCA trial. We reported the outcome of mCRPC pts with bone mets receiving Ra-223 as 2nd-line therapy after ABI/ENZ.
Methods
We collected data that pts using ABI/ENZ as 1st-line therapy for mCRPC and symptomatic bone mets followed by Ra-223. Pts received docetaxel in mCSPC were excluded. We evaluated the clinical outcomes of this population.
Results
From Jan 2020 to Jun 2023, 13 pts received Ra-223 as 2nd-line. Median follow-up was 15.7 mos (1.7-27.3). Median radiographic PFS was 6.5 mos and median OS was 10.2 mos. 7 pts had mediastinal or paraaortic lymph nodes (LNs) in CT scan before Ra-223. 10 pts had PSA progression during Ra-223 (6 of them had prominent LN and 4 could not complete 6 cycles due to lung and liver mets). 3 pts without LNs had stable PSA including 1 pt had PSA >30% reduction. The median calculated PSA doubling time (PSADT) was 5.6 mos (0.9-16) and PSADT < 3 mos passed away rapidly. For pts progression after Ra-223, they kept on ADT but no PSA response was found. 4 pts received docetaxel, enzalutamide or local RT as salvage therapies. One received oral cyclophosphamide as 4th-line after 3rd-line docetaxel and had a PSA reduction >50% and was still alive >12 mos without progression. The major adverse effect of Ra-223 was Gr. 3 anemia. 4 pts decreased opioid use after Ra-223. Table: 280P
Patients' characteristics | N = 13 |
Mean age (years) | 79 [62 - 93] |
ECOG PS 0-1 | 7 |
ECOG PS >=2 | 6 |
Gleason score | |
3+4 | 4 |
4+5 | 8 |
5+5 | 1 |
Initial T stage | |
T2 | 1 |
T3 | 9 |
T4 | 3 |
Initial N stage | |
N0 | 4 |
N1 | 9 |
Local RT to prostate or prostatectomy | 8 |
Bone metastases at diagnosis | 12 |
First-line treatment for mCRPC | Abiraterone (ABI): 10 |
Enzalutamide (ENZ): 3 | |
Median treatment duration of ABI/ENZ (mos) | 16.7 [9.8 - 36.3] |
Median Serum PSA before Ra-223 (ng/dL) | 55.7 [4.8 - 488.7] |
Pts with lymph nodes in CT prior to Ra-223 | 7 |
Median radiographic PFS of Ra-223 (mos) | 6.5 [1.8 - 14.1] |
Sequential systemic therapies | Docetaxel: 4 (3rd-line) |
Enzalutamide: 1 (4rd-line) | |
Oral cyclophosphamide: 1 (4th-line) | |
Median OS of Ra-223 (mos) | 10.2 [2.0 - 25.6] |
Conclusions
Ra-223 use after first-line ABI/ENZ for mCRPC with bone mets should be cautious if pts had prominent LNs. PSA progression during or after Ra-223 leads to poor outcome and salvage therapy should be given earlier.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract